Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,251
archived clinical trials in
Pneumonia

Endotracheal Tubes for Prevention of Ventilator-associated Pneumonia
Pilot Trial of Tubes to Prevent Ventilator-Associated Pneumonia (PreVent)
Status: Enrolling
Updated:  9/25/2017
Harborview Medical Center
mi
from
Seattle, WA
Endotracheal Tubes for Prevention of Ventilator-associated Pneumonia
Pilot Trial of Tubes to Prevent Ventilator-Associated Pneumonia (PreVent)
Status: Enrolling
Updated: 9/25/2017
Harborview Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Rapid Empiric Treatment With Oseltamivir Study (RETOS)
Title: Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia During the Influenza Season (U18)
Status: Enrolling
Updated:  10/3/2017
Jewish Hospital
mi
from
Louisville, KY
Rapid Empiric Treatment With Oseltamivir Study (RETOS)
Title: Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia During the Influenza Season (U18)
Status: Enrolling
Updated: 10/3/2017
Jewish Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Rapid Empiric Treatment With Oseltamivir Study (RETOS)
Title: Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia During the Influenza Season (U18)
Status: Enrolling
Updated:  10/3/2017
Norton Hospital
mi
from
Louisville, KY
Rapid Empiric Treatment With Oseltamivir Study (RETOS)
Title: Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia During the Influenza Season (U18)
Status: Enrolling
Updated: 10/3/2017
Norton Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Rapid Empiric Treatment With Oseltamivir Study (RETOS)
Title: Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia During the Influenza Season (U18)
Status: Enrolling
Updated:  10/3/2017
University of Louisville Hospital
mi
from
Louisville, KY
Rapid Empiric Treatment With Oseltamivir Study (RETOS)
Title: Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia During the Influenza Season (U18)
Status: Enrolling
Updated: 10/3/2017
University of Louisville Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Rapid Empiric Treatment With Oseltamivir Study (RETOS)
Title: Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia During the Influenza Season (U18)
Status: Enrolling
Updated:  10/3/2017
Rex Robley VA Medical Center
mi
from
Louisville, KY
Rapid Empiric Treatment With Oseltamivir Study (RETOS)
Title: Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia During the Influenza Season (U18)
Status: Enrolling
Updated: 10/3/2017
Rex Robley VA Medical Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Rapid Empiric Treatment With Oseltamivir Study (RETOS)
Title: Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia During the Influenza Season (U18)
Status: Enrolling
Updated:  10/3/2017
Baptist Hospital East
mi
from
Louisville, KY
Rapid Empiric Treatment With Oseltamivir Study (RETOS)
Title: Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia During the Influenza Season (U18)
Status: Enrolling
Updated: 10/3/2017
Baptist Hospital East
mi
from
Louisville, KY
Click here to add this to my saved trials
Pneumococcal Adult-dose Ranging Immunization Study
Immunogenicity and Safety of Varying Doses of a 7-valent Conjugate Pneumococcal Vaccine in Adults 70-79 Years of Age Who Were Previously Vaccinated With the 23-valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated:  10/11/2017
Group Health Research Institute
mi
from
Seattle, WA
Pneumococcal Adult-dose Ranging Immunization Study
Immunogenicity and Safety of Varying Doses of a 7-valent Conjugate Pneumococcal Vaccine in Adults 70-79 Years of Age Who Were Previously Vaccinated With the 23-valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated: 10/11/2017
Group Health Research Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Pneumococcal Adult-dose Ranging Immunization Study
Immunogenicity and Safety of Varying Doses of a 7-valent Conjugate Pneumococcal Vaccine in Adults 70-79 Years of Age Who Were Previously Vaccinated With the 23-valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated:  10/11/2017
VA Puget Sound Health Care System
mi
from
Seattle, WA
Pneumococcal Adult-dose Ranging Immunization Study
Immunogenicity and Safety of Varying Doses of a 7-valent Conjugate Pneumococcal Vaccine in Adults 70-79 Years of Age Who Were Previously Vaccinated With the 23-valent Pneumococcal Polysaccharide Vaccine
Status: Enrolling
Updated: 10/11/2017
VA Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
San Francisco, CA
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Aurora, CO
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Miami, FL
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Orlando, FL
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Louisville, KY
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Durham, NC
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Cleveland, OH
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Columbus, OH
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Portland, OR
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Nashville, TN
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Dallas, TX
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Falls Church, VA
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Falls Church, VA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
mi
from
Mar del Plata,
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
mi
from
Mar del Plata,
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Via Christi Clinic
mi
from
Wichita, KA
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Via Christi Clinic
mi
from
Wichita, KA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Columbia University Medical Center
mi
from
New York, NY
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome
Relationship of Pulmonary Contusion Morphology to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome
Status: Enrolling
Updated:  11/2/2017
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome
Relationship of Pulmonary Contusion Morphology to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome
Status: Enrolling
Updated: 11/2/2017
Wake Forest Baptist Health
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
University of Colorado
mi
from
Colorado Springs, CO
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
University of Colorado
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
Denver Health
mi
from
Denver, CO
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
Denver Health
mi
from
Denver, CO
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
Atlanta VA Medical Center
mi
from
Atlanta, GA
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
Atlanta VA Medical Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
University of Kentucky
mi
from
Lexington, KY
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
University of Maryland Medical Center
mi
from
Baltimore, MD
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
Baystate Medical Center
mi
from
Springfield, MA
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
Baystate Medical Center
mi
from
Springfield, MA
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
Moses Cone
mi
from
Greensboro, NC
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
Moses Cone
mi
from
Greensboro, NC
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
Cleveland Clinic
mi
from
Cleveland, OH
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
Ohio State University
mi
from
Columbus, OH
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
Legacy Emanuel Medical Center
mi
from
Portland, OR
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
Legacy Emanuel Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
Legacy Good Samaritan Medical Center
mi
from
Portland, OR
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
Legacy Good Samaritan Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
Rhode Island Hospital
mi
from
Providence, RI
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
Baylor
mi
from
Houston, TX
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
Baylor
mi
from
Houston, TX
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
Memorial Hermann Hospital, Texas Medical Center
mi
from
Houston, TX
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
Memorial Hermann Hospital, Texas Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
South Texas Veterans Health Care System
mi
from
San Antonio, TX
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
South Texas Veterans Health Care System
mi
from
San Antonio, TX
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
Scott & White Memorial Hospital
mi
from
Temple, TX
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
Scott & White Memorial Hospital
mi
from
Temple, TX
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
Intermountain Medical Center
mi
from
Murray, UT
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
Intermountain Medical Center
mi
from
Murray, UT
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
University of Utah
mi
from
Salt Lake City, UT
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
University of Virginia
mi
from
Charlottesville, VA
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated:  11/7/2017
Northwestern University
mi
from
Chicago, IL
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
Status: Enrolling
Updated: 11/7/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials